Phase 1/2 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally, Advanced, Non-Resectable or Metastatic Urothelial Cancer.

Trial Profile

Phase 1/2 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally, Advanced, Non-Resectable or Metastatic Urothelial Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Cisplatin; Pemetrexed
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 Jun 2009 Actual number of patients changed from 54 to 59 as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 25 Jun 2008 The expected completion date for this trial is now 1 Dec 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top